Valérie Journot

Summary

Country: France

Publications

  1. ncbi Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods
    V Journot
    INSERM U330, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Control Clin Trials 22:639-58. 2001
  2. ncbi Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099
    Valérie Journot
    INSERM, U593, Bordeaux, France
    Clin Infect Dis 42:1790-9. 2006
  3. ncbi About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE
    Valérie Journot
    INSERM, U593, F 33076 Bordeaux, France
    Contemp Clin Trials 29:95-101. 2008
  4. ncbi Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
    HIV Clin Trials 4:417-20. 2003
  5. ncbi Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy
    Genevieve Chene
    INSERM, U593, F 33076 Bordeaux, France
    AIDS Res Hum Retroviruses 23:54-61. 2007
  6. ncbi Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients
    Genevieve Chene
    INSERM Unité 330, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Clin Infect Dis 34:649-57. 2002
  7. ncbi Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study
    Valérie Journot
    INSERM, U897, F 33076 Bordeaux, France
    Contemp Clin Trials 32:16-24. 2011

Detail Information

Publications7

  1. ncbi Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods
    V Journot
    INSERM U330, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Control Clin Trials 22:639-58. 2001
    ....
  2. ncbi Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099
    Valérie Journot
    INSERM, U593, Bordeaux, France
    Clin Infect Dis 42:1790-9. 2006
    ..Whether the use of EFV is associated with the risk of depression or suicide remains controversial...
  3. ncbi About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE
    Valérie Journot
    INSERM, U593, F 33076 Bordeaux, France
    Contemp Clin Trials 29:95-101. 2008
    ....
  4. ncbi Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
    HIV Clin Trials 4:417-20. 2003
    ..The potential for loss of information might yield differential misclassification biases and therefore unreliable results. Longitudinal models are better suited to analyze the repeated measures of a continuous outcome such as HIV RNA...
  5. ncbi Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy
    Genevieve Chene
    INSERM, U593, F 33076 Bordeaux, France
    AIDS Res Hum Retroviruses 23:54-61. 2007
    ..Furthermore, a low mtDNA level at month 12 was associated with the subsequent development of lipodystrophy. This marker may be of value for the early prevention of lipodystrophy in treated HIV-infected patients...
  6. ncbi Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients
    Genevieve Chene
    INSERM Unité 330, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Clin Infect Dis 34:649-57. 2002
    ..4; P=.007). No difference was observed in cholesterol and glucose levels as a function of any pattern of antiretroviral exposure. Exposure to stavudine and didanosine was associated with LD syndrome (predominantly lipoatrophy)...
  7. ncbi Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study
    Valérie Journot
    INSERM, U897, F 33076 Bordeaux, France
    Contemp Clin Trials 32:16-24. 2011
    ..Standardization is needed, and relies on definition and validation of tools accounting for risk...